Nuformix PLC Result of General Meeting (1561A)
January 31 2022 - 6:04AM
UK Regulatory
TIDMNFX
RNS Number : 1561A
Nuformix PLC
31 January 2022
Nuformix plc
("Nuformix" or the "Company")
Result of General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, confirms that, further to the announcement made in
connection with the Subscription to raise GBP1.65 million with
Lanstead Capital Investors L.P., at the General Meeting held
earlier today all Resolutions were passed by way of a poll, the
full results of which are given below:
Resolution Ordinary/ For Against Total votes
Special cast
No. of % No. of %
votes votes
THAT, in addition
to existing authorities,
the directors are
authorised to exercise
all powers of the
Company to allot
1 new ordinary shares Ordinary 81,448,911 95.22% 4,093,030 4.78% 85,541,941
THAT, upon the passing
of Resolution 1,
the Directors be
empowered to allot
new ordinary shares
for cash on a non-pre-emptive
2 basis. Special 81,438,942 95.19% 4,116,235 4.81% 85,555,177
Accordingly, the Company now has sufficient authorities in place
to allot the Second Subscription Shares and the Second Value
Payment Shares. The Second Subscription remains conditional on
there being no requirement for the Company to publish a prospectus
in connection with the Second Subscription. It is expected that the
Second Subscription Shares and the Second Value Payment Shares will
be issued in April 2022 and at that point application will be made
to the London Stock Exchange and the Financial Conduct Authority
for Admission.
Notes:
1. Any proxy arrangement which gave discretion to the Chairman
has been included in the "for" totals.
2. A "Vote withheld" is not a vote in law and is not counted in
the calculation of the percentage of shares voted "For" or
"Against" any resolution.
3. The number of shares in issue at close of business on 28
January 2022 was 615,609,368. The Company does not hold any shares
in treasury.
Unless otherwise defined, all capitalised terms used but not
defined in this announcement shall have the meaning given to them
in the Circular dated 14 January 2022, a copy of which is available
to view on the Company's website ( www.nuformix.com ).
Enquiries:
Nuformix plc via Walbrook
Dr Alastair Riddell, Executive
Chairman
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44 (0)20 7933 8780
Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44 (0)7867
984 082
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase I-ready assets with potential for significant value and
early licensing opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMGZGFMMMMGZZM
(END) Dow Jones Newswires
January 31, 2022 06:04 ET (11:04 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024